Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;17(1):344-348.
doi: 10.3892/etm.2018.6914. Epub 2018 Nov 1.

Correlation of clinical features with hs-CRP in TRD patients

Juan Qiao  1 , Deqin Geng  2 , Liju Qian  3 , Xianghua Zhu  1 , Houfeng Zhao  4
Affiliations

Correlation of clinical features with hs-CRP in TRD patients

Juan Qiao et al. Exp Ther Med. 2019 Jan.

Abstract

Correlation of clinical features with hypersensitive C-reactive protein (hs-CRP) in patients with treatment-resistant depression (TRD) was investigated. The severity of disease in 103 TRD patients and 103 non-TRD patients was evaluated using the Hamilton Depression Scale (HAMD)-17. The levels of hs-CRP in both groups were detected via immunofluorescence. Clinical features and differences in hs-CRP before and after treatment in both groups were analyzed, and correlation of baseline hs-CRP level with clinical features of TRD patients was also analyzed. Moreover, the relationship between hs-CRP and occurrence of TRD was analyzed using logistic regression analysis, and the diagnostic value of hs-CRP in TRD was evaluated using the receiver operating characteristic (ROC) curve. The onset age in the TRD group was lower than that in the non-TRD group, the education in the TRD group was shorter than that in the non-TRD group, the total course of disease in the TRD group was longer than that in the non-TRD group, and both baseline and post-treatment hs-CRP level in the TRD group (12.05±5.79 and 9.02±3.71 mg/l) were higher than those in the non-TRD group (7.85±2.85 and 6.10±2.74 mg/l) (p<0.05). The HAMD score (r=0.338, p=0.031), anxiety/somatization factor score (r=0.465, p=0.015) and sleep disorder (r=0.387, p=0.029) of TRD patients were positively correlated with the hs-CRP level, but the onset age (r=-0.59, p=0.009) was negatively correlated with the hs-CRP level. Logistic regression analysis revealed that the baseline hs-CRP was included into the TRD regression equation [odds ratio (OR) =2.834, 95% confidence interval (CI) =1.723-4.886], and the area under the ROC curve was 0.893 (p<0.05, 95% CI=0.852-0.933). In the TRD group, the course of TRD in patients was longer, the onset of disease was earlier and the educational level was lower than that in the non-TRD group. Therefore, the level of hs-CRP can serve as a reference for the diagnosis of TRD.

Keywords: clinical features; hypersensitive C-reactive protein; treatment-resistant depression.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
ROC curve of hs-CRP in the diagnosis of TRD. ROC, receiver operating characteristic; hs-CRP, hypersensitive C-reactive protein; TRD, treatment-resistant depression.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wiles N, Thomas L, Abel A, Barnes M, Carroll F, Ridgway N, Sherlock S, Turner N, Button K, Odondi L, et al. Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: The CoBalT randomised controlled trial. Health Technol Assess. 2014;18:1–167. doi: 10.3310/hta18310. vii-viii. - DOI - PMC - PubMed
    1. Swaab DF, Fliers E, Hoogendijk WJ, Veltman DJ, Zhou JN. Interaction of prefrontal cortical and hypothalamic systems in the pathogenesis of depression. Prog Brain Res. 2000;126:369–396. doi: 10.1016/S0079-6123(00)26025-1. - DOI - PubMed
    1. van Waarde JA, Scholte HS, van Oudheusden LJ, Verwey B, Denys D, van Wingen GA. A functional MRI marker may predict the outcome of electroconvulsive therapy in severe and treatment-resistant depression. Mol Psychiatry. 2015;20:609–614. doi: 10.1038/mp.2014.78. - DOI - PubMed
    1. Schneider B, Prvulovic D. Novel biomarkers in major depression. Curr Opin Psychiatry. 2013;26:47–53. doi: 10.1097/YCO.0b013e32835a5947. - DOI - PubMed
    1. Conway CR, Gebara MA, Walker MC, Lessov-Schlaggar CN, Janski AM, Chibnall JT, Cristancho P, Sheline YI, Gott BM, Svrakic DM. Clinical characteristics and management of treatment-resistant depression. J Clin Psychiatry. 2015;76:1569–1570. doi: 10.4088/JCP.14l09462. - DOI - PubMed